ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Hydration practices during cisplatin administration: a national multicenter survey.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCisplatin-based chemotherapy remains a cornerstone of cancer treatment, yet optimal strategies to prevent nephrotoxicity through hydration protocols remain controversial. While both long and short hydration regimens are commonly used, no consensus exists on the most effective approach. Emerging data suggest that short hydration protocols may offer comparable nephroprotection while improving quality of life and facilitating outpatient care.
methodsA national, multicenter survey was conducted to evaluate hydration practices among French oncology professionals prescribing cisplatin. A working group of oncologists and nephrologists developed a 28-question survey, covering demographics, hydration protocols, electrolytes and diuretic use, and renal function monitoring. The survey was distributed online between March and June 2024 to medical oncologists, hematologists, radiation oncologists, pharmacists, and other relevant specialists involved in chemotherapy prescribing. Data were analyzed using descriptive statistics and appropriate statistical tests to compare variables.
resultsAmong 173 respondents, most were medical oncologists (61%) or radiation oncologists (20%), practicing mainly in university hospitals (38%) or comprehensive cancer centers (22%). Hydration protocols commonly used varied among respondents, with long (> 24 h, 3.5-4L) or short (≤ 4.5 h, 2-2.5L) regimens used by 73% and 16% of respondents respectively. Renal function was most commonly assessed by CKD-EPI (52%) or MDRD (42%). A creatinine clearance threshold of 60 mL/min was used to contraindicate cisplatin by 72% of respondents, especially those with ≤ 10 years of experience (p = 0.015), and 50 mL/min by 24%. Hospital-based hydration was more common in public institutions (p = 0.021), while private centers preferred home-based strategies (p < 0.001). Magnesium (57%) and potassium (37%) were routinely supplemented.
conclusionThis study highlights the substantial heterogeneity of hydration practices for cisplatin administration in France, contrasting with the increasing international adoption of short outpatient regimens. These findings underscore the need for updated, evidence-based national and international guidelines to harmonize practices, optimize nephroprotection, and facilitate the safe expansion of outpatient and home hydration models.
Indexed as
Identifiers
41288783What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.